MNKD
Price
$3.98
Change
+$0.21 (+5.57%)
Updated
Jul 14, 04:14 PM (EDT)
Capitalization
1.15B
23 days until earnings call
PDSB
Price
$1.24
Change
-$0.06 (-4.62%)
Updated
Jul 11 closing price
Capitalization
56.68M
30 days until earnings call
Interact to see
Advertisement

MNKD vs PDSB

Header iconMNKD vs PDSB Comparison
Open Charts MNKD vs PDSBBanner chart's image
MannKind
Price$3.98
Change+$0.21 (+5.57%)
Volume$232
Capitalization1.15B
PDS Biotechnology
Price$1.24
Change-$0.06 (-4.62%)
Volume$449.54K
Capitalization56.68M
MNKD vs PDSB Comparison Chart in %
Loading...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNKD vs. PDSB commentary
Jul 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNKD is a Hold and PDSB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2025
Stock price -- (MNKD: $3.77 vs. PDSB: $1.24)
Brand notoriety: MNKD and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNKD: 72% vs. PDSB: 70%
Market capitalization -- MNKD: $1.15B vs. PDSB: $56.68M
MNKD [@Biotechnology] is valued at $1.15B. PDSB’s [@Biotechnology] market capitalization is $56.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $318.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNKD’s FA Score shows that 0 FA rating(s) are green whilePDSB’s FA Score has 1 green FA rating(s).

  • MNKD’s FA Score: 0 green, 5 red.
  • PDSB’s FA Score: 1 green, 4 red.
According to our system of comparison, both MNKD and PDSB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNKD’s TA Score shows that 5 TA indicator(s) are bullish while PDSB’s TA Score has 4 bullish TA indicator(s).

  • MNKD’s TA Score: 5 bullish, 3 bearish.
  • PDSB’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, MNKD is a better buy in the short-term than PDSB.

Price Growth

MNKD (@Biotechnology) experienced а +4.72% price change this week, while PDSB (@Biotechnology) price change was -6.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +13.18%. For the same industry, the average monthly price growth was +23.64%, and the average quarterly price growth was +32.83%.

Reported Earning Dates

MNKD is expected to report earnings on Nov 11, 2025.

PDSB is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+13.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNKD($1.15B) has a higher market cap than PDSB($56.7M). PDSB YTD gains are higher at: -23.926 vs. MNKD (-41.369). MNKD has higher annual earnings (EBITDA): 82.6M vs. PDSB (-33.08M). MNKD has more cash in the bank: 182M vs. PDSB (40M). PDSB has less debt than MNKD: PDSB (19M) vs MNKD (47.2M). MNKD has higher revenues than PDSB: MNKD (298M) vs PDSB (0).
MNKDPDSBMNKD / PDSB
Capitalization1.15B56.7M2,021%
EBITDA82.6M-33.08M-250%
Gain YTD-41.369-23.926173%
P/E Ratio37.70N/A-
Revenue298M0-
Total Cash182M40M455%
Total Debt47.2M19M248%
FUNDAMENTALS RATINGS
MNKD vs PDSB: Fundamental Ratings
MNKD
PDSB
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
32
Undervalued
PROFIT vs RISK RATING
1..100
61100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
8665
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PDSB's Valuation (32) in the Pharmaceuticals Major industry is in the same range as MNKD (47) in the Biotechnology industry. This means that PDSB’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Profit vs Risk Rating (61) in the Biotechnology industry is somewhat better than the same rating for PDSB (100) in the Pharmaceuticals Major industry. This means that MNKD’s stock grew somewhat faster than PDSB’s over the last 12 months.

PDSB's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as MNKD (100) in the Biotechnology industry. This means that PDSB’s stock grew similarly to MNKD’s over the last 12 months.

PDSB's Price Growth Rating (65) in the Pharmaceuticals Major industry is in the same range as MNKD (86) in the Biotechnology industry. This means that PDSB’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's P/E Growth Rating (98) in the Biotechnology industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that MNKD’s stock grew similarly to PDSB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNKDPDSB
RSI
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
77%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
89%
MACD
ODDS (%)
Bullish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 6 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
72%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EQMEF0.190.02
+13.10%
Equity Metals Corporation
MFGCF1.200.01
+0.50%
Mayfair Gold Corp.
MAKSF4.90N/A
N/A
Marks & Spencer Group Plc
OSSUY4.00N/A
N/A
EMBLA MEDICAL
CNTHP51.68N/A
N/A
Connecticut Light & Power Co. (The)

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with ARCT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
-4.62%
ARCT - PDSB
50%
Loosely correlated
-4.83%
RXRX - PDSB
48%
Loosely correlated
-7.61%
DYN - PDSB
45%
Loosely correlated
-1.82%
ATOS - PDSB
45%
Loosely correlated
+5.70%
CRNX - PDSB
44%
Loosely correlated
-0.19%
More